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INTRODUCTION
Animal models of disease provide an important opportunity to test
the action of existing drugs in new disease contexts. Germline
mutations in the RAS-MAPK signalling cascade are found in a
spectrum of overlapping developmental syndromes, collectively
referred to as the ‘RASopathies’ (Tidyman and Rauen, 2009). Rare
genetic developmental disorders such as RASopathies are not a
focus of drug development. However, drugs with high specificity
and efficacy for the RAS-MAPK pathway, although designed as
anti-cancer therapies, are obvious potential therapies for
RASopathies (Sebolt-Leopold, 2008; Rauen et al., 2011; Pratilas and
Solit, 2010). PD0325901 is a highly selective small-molecule
inhibitor of MEK1 and MEK2 in vitro and in vivo (Sebolt-Leopold,
2008). In clinical trials, PD0325901 has shown effective inhibition
of MEK activity for individuals with MAPK-activated solid tumours
(Haura et al., 2010; LoRusso et al., 2010). Thus, although designed
as anti-cancer drugs, MEK inhibitors hold potential for use in
additional clinical settings.
The RASopathies spectrum includes cardio-facio-cutaneous
syndrome (CFC), Costello syndrome (CS), Noonan syndrome
(NS), LEOPARD syndrome (LS), neurofibromatosis type 1 (NF1)
and Legius syndrome. Clinical features of CFC syndrome include
heart malformations, prominent facial features, sparse eyebrows,
curly hair, increased number of nevi and neurocognitive delay
(Roberts et al., 2006). In vitro analysis of the mutations in BRAF
and MEK that are identified in individuals with CFC syndrome has
shown some to be kinase-activating and some kinase-impaired
(Rodriguez-Viciana et al., 2006). However, we have shown that all
tested CFC mutations have gain-of-function activity in vivo
(Anastasaki et al., 2009). Expression of BRAFCFC and MEKCFC
mutant alleles in zebrafish embryos causes cell movement defects
during early development, indicative of activated FGF-MAPK
signalling in gastrulation cell movements (convergence-extension)
(Krens et al., 2008). In vitro, kinase-activating MEKCFC mutations
are responsive to inhibition of MEK and RAF (Senawong et al.,
2008). In vivo, FGFR and MEK inhibitors can prevent cell
movement defects in BRAFCFC- and MEKCFC-expressing zebrafish
embryos (Anastasaki et al., 2009). Notably, in our early embryonic
CFC model, a 1-hour treatment window at 4 hours postfertilisation
(hpf) was sufficient to restore normal gastrulation and embryonic
formation up to 24 hpf (Anastasaki et al., 2009).
However, identification of an early development treatment
window is not easily extrapolated to a timed treatment of embryos
in utero. Moreover, embryos that had undergone longer treatments
often had serious additional developmental defects associated with
strong inhibition of MEK activity. Here, we use the zebrafish system
as a model for continuous low-level MEK inhibition in developing
vertebrates. First, we perform a detailed analysis of the effects of
ten different doses of PD0325901 and assess the impact during the
first 5 days of development. Notably, a very low treatment dose
with only minimal MEK inhibition is sufficient to prevent the
deleterious effects of BRAFCFC in developing zebrafish. We suggest
that continuous minimal inhibition of MAPK signalling might be
sufficient to prevent some of the developmental features caused by
CFC mutations in developing children. This study provides a proof-
of-principle that low treatment doses of kinase inhibitors can be
effective in ameliorating the effects of CFC alleles in development,
and could be crucial for designing future CFC syndrome clinical
trials (Rauen et al., 2010; Rauen et al., 2011).
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SUMMARY
Cardio-facio-cutaneous (CFC) syndrome is caused by germline mutations in KRAS, BRAF and MEK1/2. The highly selective and potent MEK inhibitors
that have been developed as anti-cancer agents hold potential as therapeutics for CFC syndrome. We have previously shown that the effects of CFC
mutations on zebrafish gastrulation can be prevented by a 1-hour treatment with MEK inhibitors within a specific developmental time-window.
However, MEK activity is essential for normal development and PD0325901 treatment outside this treatment window leads to additional
developmental defects in MEK-dependent tissues. We now test ten different doses of PD0325901 at six developmental time points and assess the
effects on body axis length, heart development and craniofacial structures in zebrafish embryos. Notably, we find that a continuous low-level dose
of PD0325901 that has only minor inhibition of MEK activity can prevent the action of both the common CFC BRAFQ257R kinase-active allele and the
BRAFG596V kinase-impaired mutant allele through the first 5 days of development. These results provide a detailed study of the effects of PD0325901
in development and show that, unlike in cancer, which requires robust inhibition of MAPK signalling, a partial reduction in phospho-ERK1/2 activity
is sufficient to moderate the developmental effects of BRAFCFC mutations.
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RESULTS
Effective MEK inhibition by PD0325901 in zebrafish development
MEK signalling is crucial for normal embryonic development. We
have previously found that the MEK inhibitor PD0325901 (Fig. 1A)
effectively inhibits phospho-ERK1/2 activity in zebrafish and is able
to counter the effects of mutant BRAF and MEK signalling in
gastrulation (Anastasaki et al., 2009). However, this dose has
deleterious effects on other developing organs (Anastasaki et al.,
2009; Grzmil et al., 2007). To determine whether low-level MEK
inhibition can be tolerated during development, we tested different
concentrations of PD0325901 during the first 4 days of
development. First, we tested a range of PD0325901 doses to
determine suboptimal concentrations as measured by levels of
phospho-ERK1/2 in the whole embryo. Zebrafish embryos (4 hpf)
were treated with increasing concentrations of PD0325901 for 6
hours, and protein extracts from the whole animal were measured
for phospho-ERK1/2 activity (Fig. 1B). Although all embryos
expressed approximately equal levels of total ERK1/2 protein,
almost all phospho-ERK1/2 isoforms were lost after 0.7 mM
PD0325901 treatment and strong reductions in phospho-ERK1/2
signals were detected with 0.5 and 0.6 mM PD0325901. At 0.1 mM,
at least half of the phospho-ERK1/2 isoforms remained detectable.
Thus, PD0325901 treatment can be tightly calibrated to generate
a range of phospho-ERK1/2 levels in the developing embryo.
Western blots provide an indication of the overall level of
MAPK signalling; however, the MAPK signalling pathway is
activated in a highly specific temporal and spatial manner during
development. We wanted to visualize how PD0325901 affected
MAPK signalling in developing tissues. Dusp6 is a protein
phosphatase that is upregulated by FGF-MAPK signalling as part
of a regulatory negative-feedback loop. The transgenic zebrafish
line expressing GFP from the dusp6 promoter (dusp6-GFP) (Molina
et al., 2007) allows for visualization of activated MAPK signalling
in living tissues, including the developing tail bud, the brain and
pharyngeal arches (Fig. 1C). Treatment with 0.5 mM PD0325901
from 4 hpf to 24 hpf caused a reduction in GFP levels in all tissues,
with reduced levels remaining in the developing tail bud and brain
(red arrows, Fig. 1C). Treatment with 1.0 mM conferred even greater
losses of GFP signal, such that almost no signal was detectable
during epiboly, and very minor levels were detected in the brain
coupled with a complete loss of signal detectable in the tail bud
(Fig. 1C). These data show that PD0325901 treatment can
effectively target the MAPK pathway within multiple tissues in the
developing zebrafish.
Systematic analysis of the MEK inhibitor PD0325901 in zebrafish
development
We next wanted to determine whether there was an effective MEK
inhibitor treatment dose that could be tolerated by wild-type
developing zebrafish. Wild-type zebrafish embryos were collected
at 4, 10, 24, 30, 48 and 72 hpf, and 40-60 embryos at each stage
were treated with ten different doses of PD0325901 (ranging from
0.1-1.0 mM) (Fig. 2A). The embryos were imaged daily and assessed
for their overall length, craniofacial development (by Alcian Blue
staining) and heart development (Fig. 2A; supplementary material
Figs S1-S3) (Grzmil et al., 2007). Phenotypes were scored from none
(0) to mild (+), moderate (++) and severe (+++). Scores were then
translated to a colour (blue, yellow, orange and red, respectively)
and arranged as a heat map. In this way, a visual overview of over
500 data points could be rapidly assessed (Fig. 2B).
FGF-MAPK signalling is required for gastrulation cell
movements that determine the development of the posterior body
length. We found that embryos were highly sensitive to PD0325901
when treated before 4 hpf (data not shown). Embryos treated at 4
hpf had a shorter anteroposterior (A-P) axis, which correlated with
dose such that concentrations above 0.6 mM PD0325901 led to a
severely shortened embryo whereas 0.2-0.4 mM of the drug caused
only a mild effect on embryo length, and 0.1 mM had no effect on
the length of the A-P axis (supplementary material Fig. S1). These
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Fig. 1. PD0325901 is an effective MEK inhibitor in zebrafish development.
(A)Chemical structure of the selective MEK inhibitor PD0325901. (B)Western
blot of 10-hpf zebrafish embryos treated with increasing concentrations of
PD0325901 from 4 hpf, and immunostained with anti-phospho-ERK1/2 and
anti-ERK1/2 antibodies. (C)Images of developing zebrafish treated with DMSO,
or 0.5mM or 1.0mM PD0325901. Zebrafish were imaged under brightfield
lighting conditions (top row), or using fluorescence microscopy to visualise
GFP expressed from the dusp6 promoter (dusp6-GFP; bottom row). GFP signal
was first detected in gastrulating embryos at 50-60% epiboly (white
arrowhead). The expression area expanded towards the vegetal pole during
epiboly (white arrowhead) and at the tail-bud stage the expression was more
diffused with higher expression levels at the tail bud (yellow arrowhead). By 24
hpf, GFP expression was detected in the brain (red arrowhead), along the
spinal column and in the tail bud (yellow arrowhead). n30 embryos per
treatment condition.
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results were consistent with our observations in the dusp6-GFP
line (Fig. 1C), in which MAPK activity in the gastrulating embryo
was reduced by treatment with 0.5 mM PD0325901 and almost
undetectable with 1.0 mM PD0325901 treatment conditions. Drug
administration at time points after 4 hpf had no effect on the A-P
body axis, consistent with an early role for FGF-MAPK in
establishing body length. Thus, MEK activity is essential before 10
hpf but A-P body axis development can tolerate a partial reduction
in MAPK signalling below a specific dose threshold.
The vertebrate jaw derives from neural crest cells and activated
MAPK signalling is required for proper specification of craniofacial
components (Walshe and Mason, 2003; Crump et al., 2004; Wilson
et al., 2004; Komisarczuk et al., 2008). Pharyngeal arch development
was highly sensitive to PD0325901 treatment, with the most severe
phenotype being associated with early and high (0.8-1.0 mM
PD0325901) treatment conditions. The first and second branchial
arches (BAs) were the least sensitive to the drug, and treatments
after 24 hpf had no effect on the first BA and minimal effects on
the second BA. Arches 3, 4 and 5 were highly sensitive to MEK
inhibition at 4 hpf and 10 hpf (0.7-1.0 mM), with embryos becoming
progressively less sensitive as they developed passed 24 hpf.
Formation of the Meckel’s cartilage (MC) and ceratohyal cartilage
(CH) were highly affected by MEK inhibition; concentrations as
low as 0.5 mM PD0325901 at 4 hpf and 0.8 mM PD0325901 at 48
hpf caused moderate-to-severe anomalies (supplementary material
Fig. S2). MEK inhibition in embryos older than 3 days
postfertilisation (dpf ) did not promote an overt craniofacial
abnormal phenotype (data not shown), probably because all visible
structures were already formed. These findings indicate that
zebrafish jaw development is highly sensitive to PD0325901
dmm.biologists.org548
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Fig. 2. Wild-type embryo sensitivity to PD0325901 treatments. (A)Schematic overview of the design of the PD0325901 treatment regimes. Wild-type
embryos were treated with ten increasing concentrations of PD0325901 (0.1-1.0mM) to identify the most affected tissues at different stages during development.
Zebrafish embryos were treated at six different developmental stages (4, 10, 24, 30, 48 and 72 hpf) until 96 hpf. The embryos were monitored daily and were
assessed for body axis, cardiac morphology and craniofacial structure phenotypes at 96 hpf. (B)Heat-map of tissue sensitivity to PD0325901 treatment. Each
panel shows tissue sensitivity after the addition of increasing concentrations of PD0325901 (0.1-1.0mM) at a different time in development. Phenotypes were
scored for sensitivity to PD0325901, and these data were translated to a colour score in the heat map: 0, no phenotype, blue; +, mild phenotype, yellow; ++,
moderate phenotype, orange; +++, severe phenotype, red. PA, pharyngeal arches; MC, Meckel’s cartilage; CH, ceratohyal cartilage; BA, branchial arches. Embryos
treated with 0.2mM PD0325901 from 4 hpf had a normal A-P axis but showed mild malformation of the tail tip (*). The heart valve of embryos treated with 0.1mM
PD0325901 from 48 hpf and with all ten concentrations of PD0325901 from 72 hpf was blocked at 5 dpf (**).
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treatment and suggests that MEK signalling is required at multiple
stages for normal jaw development.
Administration of all PD0325901 concentrations at 4, 10, 24, 30
and 48 hpf led to heart anomalies in most embryos by 4 dpf
(supplementary material Fig. S3). The phenotype was reminiscent
of that promoted by a previous generation MEK inhibitor, CI-1040
(Grzmil et al., 2007). The embryos developed cardiac oedemas and
blockage of the bulbus arteriosus, causing restricted blood flow and
exit from the heart chambers. The cardiovascular system of embryos
incubated at 72 hpf seemed to be unaffected 24 hours later, but the
embryos displayed the described aberrant cardiac phenotype after
a 48-hour incubation (data not shown). Notably, the PD0325901-
induced heart defect was always observed 2 days after treatment,
regardless of the developmental stage (Fig. 2B). Thus, although
MAPK signalling might be important for normal heart development,
these results suggest that either active MEK activity is required to
maintain heart integrity, or cardiac oedemas and valve blockage are
off-target, toxic side effects of PD0325901 treatment.
Small-molecule prevention of BRAFCFC phenotypes
Given the sensitivity of the developing zebrafish to inhibition of
MEK activity, we investigated whether low doses of PD0325901
(0.1-0.2 mM) were sufficient to suppress activity of the BRAFCFC
allele without the unwanted effects caused by the inhibitor. First,
we established our model for CFC mutant allele expression. Single-
cell embryos were injected with 35 pg of mRNA expressing either
human BRAFWT, the kinase-activating and most common CFC
mutation BRAFQ257R, or the kinase-inactivating BRAFG596V
mutation. We have previously shown that overexpression of
BRAFWT has no effect on zebrafish, suggesting that developing
embryos can compensate for the increased wild-type BRAF activity
(Fig. 3A). This is consistent with the inability of transgenic BRAFWT
to induce nevi and/or melanoma in zebrafish. By contrast,
overexpression of either BRAFQ257R or BRAFG596V promotes cell
movement defects during gastrulation, consistent with enhanced
activation of the MAPK signalling pathway in vivo (Fig. 3A). These
embryos continue to develop, but with a shortened body axis (Fig.
3A). Increased nevi count is a feature of the CFC syndrome and,
likewise, we found that transgenic BRAFG596V is also able to
promote nevi development when expressed under the melanocyte-
specific mitfa promoter (Fig. 3B). Thus, although BRAF mutations
are not expressed from the endogenous locus in our model,
BRAFCFC RNA overexpression or expression of transgenic BRAFCFC
can serve as a model for CFC mutant allele expression in animals.
Disease Models & Mechanisms 549
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Fig. 3. Continuous suboptimal PD0325901 treatment prevents zebrafish BRAFCFC phenotypes. (A)Wild-type embryos were injected with human BRAFWT,
the kinase-activating and most common CFC allele BRAFQ257R, or the kinase-inactivating BRAFG596V, and imaged at the indicated developmental time post-
fertilisation. (B)Images of untreated control zebrafish (top panel) and a zebrafish expressing the kinase-inactivating BRAFG596V allele under the melanocyte-
specific mitfa promoter (bottom panel). Insert image depicts a high-magnification image of ectopic melanisation and nevi formation. (C)Continuous treatment
of BRAFWT- and BRAFCFC-injected embryos with a suboptimal dose (0.2mM) of PD0325901 from 4 hpf through 4 dpf. (D)Western blot of 10-hpf wild-type
[uninjected (Un)] or BRAFCFC embryos treated with 0.2mM of PD0325901 from 4 hpf, and immunostained with anti-phospho-ERK1/2 and anti-ERK1/2 antibodies.
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Next, we tested the sensitivity of BRAFCFC alleles to MEK
inhibition in zebrafish embryos. We have previously shown that
BRAFCFC and MEKCFC mutations are responsive to an optimal short
treatment dose of two MEK inhibitors. We wanted to identify a
continuous and low-dose MEK inhibitor treatment that could
prevent the action of the BRAFCFC mutation while not causing
additional developmental abnormalities as a result of MEK
inhibition. Our analysis indicated that embryos had to be treated
early enough to prevent BRAFCFC gastrulation defects and with less
than 0.3 mM PD0325901 to prevent drug-induced developmental
defects. Single-cell embryos were injected with 35 pg of human
BRAFWT, BRAFQ257R or BRAFG596V mRNA and these embryos were
treated from 4 hpf to 4 dpf with a continuous dose of 0.1 or 0.2
mM PD0325901 (Fig. 3C). BRAFWT embryos treated with a
continuous 0.1 mM PD0325901 dose were grossly normal. However,
this treatment dose was insufficient to prevent the action of
BRAFQ257R and BRAFG596V activity: CFC embryos were elongated
during gastrulation and severely shortened in the A-P axis
(supplementary material Fig. S4). By comparison, BRAFQ257R and
BRAFG596V embryos treated with a continuous 0.2 mM PD0325901
dose were only mildly elongated during gastrulation and were
slightly delayed in development, but were able to develop a normal
body axis by 24 hpf (Fig. 3C). Interestingly, this treatment dose
caused a minor tail abnormality in BRAFWT embryos, suggesting
that 0.2 mM PD0325901 treatments are at the limit of tolerance for
BRAFWT-injected embryos. Despite the treatment conditions
allowing axial development, all 0.2 mM PD0325901-treated embryos
nevertheless developed a cardiac valve closure. Western blotting
confirmed that phospho-ERK1/2 was present in 0.2 mM
PD0325901-treated BRAFQ257R and BRAFG596V embryos (Fig. 3D).
Thus, in our zebrafish model, we can identify a low-dose and
permissive MEK inhibition treatment for CFC embryos.
DISCUSSION
The importance of the RAS-MAPK signalling pathway in cancer
has led to the development of highly effective and specific
inhibitors of RAS, BRAF and MEK that hold potential for the
reduction of the severity and progression of the RASopathies
(Tidyman and Rauen, 2009). Some inhibitors have already been
tested in preclinical mouse models: MEK inhibitors can effectively
limit some of the features of activated MAPK signalling in an
FGFR model of Apert syndrome, as well as in a RAF model of
Noonan syndrome (Chen et al., 2010; Wu et al., 2011). In
zebrafish, expression of RAS, BRAF and MEK Noonan and CFC
syndrome mutations cause cell movement defects that can be
prevented with the MEK inhibitors PD0325901 and/or the closely
related CI-1040 (Anastasaki et al., 2009; Runtuwene et al., 2011).
Altering the MAPK output can also restore impaired learning in
fruit flies expressing SHP2 Noonan syndrome mutations (Pagani
et al., 2009). Thus, animal models of developmental disease in a
wide range of species can respond to treatments designed to target
altered signalling in human cancer.
Short treatments with MEK inhibitors at key developmental
stages could thus prevent the serious consequences of CFC
mutations in development. This strategy is possible in zebrafish
because of the ex utero fertilization, the ability to clearly distinguish
each developmental stage under the light microscope, and the rapid
uptake of the compound from the fish water. This approach would
be much more difficult to apply to in utero mammalian models,
or even people. To address this, we tested continual MEK inhibitor
treatment in the context of a zebrafish model of CFC syndrome.
We identify three key findings relevant to MEK inhibitor treatments
in animals. First, through systematic analysis of drug-development
combinations, we identify that a 0.1-0.2 mM treatment dose of
PD0325901 has little effect on normal development. These doses
have only a partial effect on MEK activity as assessed by phospho-
ERK1/2 activity and dusp6-GFP expression. Second, continuous
treatment with a 0.2 mM dose of MEK inhibitor is sufficient to
prevent the effects of both kinase-active and kinase-impaired
BRAFCFC alleles. Thus, unlike cancer treatment strategies, which
aim to fully inhibit MEK activity (e.g. Solit et al., 2006; Sharma and
Settleman, 2007), MAPK signalling developmental disorders might
benefit from only a partial inhibition of the pathway. This concept
was also illustrated by the ability of upstream FGFR inhibitors to
rescue downstream BRAFCFC mutations in zebrafish, presumably
because reducing endogenous FGF signalling helped reduce the
total MAPK signalling output (Anastasaki et al., 2009). Interestingly,
in treatment conditions optimal for BRAFCFC embryos, the embryos
still showed some of the effects of increased MAPK signalling and
slight developmental delay at 10 hpf, but once passed this stage
developed normally. This might reflect the potential for the
developing animal to tolerate some variations in signalling provided
that it is below a critical threshold. Finally, we find that PD0325901
causes zebrafish embryonic heart defects. This effect appeared at
all treatment doses, suggesting that either MEK activity is required
to maintain heart integrity and/or that this defect reflects a toxic
side effect. By contrast, adult zebrafish can tolerate 0.01-1.0 mM
PD0325901 in fish water for at least 7 days (Jennifer Richardson,
personal communication), suggesting that the effects might be
specific to the embryonic zebrafish heart. Thus, in our model,
treatment does not necessarily require a highly effective MEK
inhibitor; however, the inhibitor needs to be highly specific in vivo
to permit normal development. The importance of small-molecule
specificity is underscored by the finding that the MEK inhibitor
U0126 also targets copper metabolism pathways in vivo (Ishizaki
et al., 2010).
Our approach provides a starting point for the potential to use
MEK inhibitors in the treatment of CFC syndrome. Other inhibitors
of the RAS-MAPK signalling pathway could also be valuable
(Wilkie, 2007; Tidyman and Rauen, 2009). For example, new BRAF
inhibitors have been highly effective in BRAF mutant melanoma
treatment (Yang et al., 2010; Chapman et al., 2011), but side effects
include the development of squamous-cell carcinomas in tissues
that lack the somatic BRAF mutation; it is unknown how BRAF
inhibitors might work in the context of germline BRAF mutations.
A recent BRAFCFC mouse model might assist in addressing this
question (Urosevic et al., 2011). The clinical features of CFC
syndrome continue to progress after birth, and MEK inhibitors
might be useful in managing and reducing the severity of clinical
features during childhood. Importantly, in the preclinical mouse
model of Noonan syndrome, postnatal administration of
PD0325901 reduced lethality and the severity of the Noonan
pathology (Chen et al., 2010; Wu et al., 2011). Although toxicity
will always be a concern, we are encouraged that very low partial
MEK inhibition treatments are effective in our zebrafish CFC
syndrome model. We suggest that animal disease models such as
dmm.biologists.org550
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this provide an important opportunity to test the action of available
drugs in disease contexts that would otherwise remain unexplored
in the drug development industry.
METHODS
Zebrafish husbandry
Adult and embryonic zebrafish were maintained and raised at
28.5°C. Embryos were collected from pair matings of wild-type AB
adults. All embryos were maintained in six-well plates in 6 ml E3
embryo medium alone, with added DMSO (control) or PD0325901.
A maximum of ten larvae were placed in each well and the medium
was refreshed daily.
Capped mRNA microinjections
Capped human mRNA was in vitro transcribed using mMESSAGE
mMACHINE (Ambion) as previously described (Anastasaki et al.,
2009). Capped BRAFQ257R mRNA (1 nl) was injected at a final
concentration of 35 ng/ml directly into the cytoplasm of one-cell-
stage wild-type embryos. Microinjections were performed using a
nitrogen-powered Picospritzer III injector (Intracel) and Nikon
SMZ 1000 dissection microscope.
Pharmacological treatment
For the systematic characterisation of the effects of PD0325901,
wild-type embryos were incubated in E3 embryo medium enriched
with PD0325901 (University of Dundee) at final concentrations
ranging from 0.1 to 1.0 mM. The medium was refreshed daily to
maintain the drug activity. For the rescue of the BRAFCFC-
expressing embryos, injected embryos were incubated in 0.1, 0.2
and 1.0 mM PD0325901 at 4 hpf. Control-treated embryos were
incubated in E3 with DMSO at the same final concentration as
PD0325901.
Immunoblotting
Immunoblotting was performed with whole-embryo lysates from
4-hpf individuals. The embryos were ribolysed for 1 minute in
protein extraction buffer [2 M Tris, pH 7.5, 5 M NaCl, 1% NP40,
Na deoxycholate, 10% SDS, 0.5 M NaF, 1 M -glycosyl phosphate,
protease inhibitor cocktail tablet (Roche)]. The protein content was
measured with a spectrophotometer and the samples were
normalized, accordingly. Total protein extracts were probed with
anti-p44/4-MAPK (1:2000; #9102) and anti-phospho-p44/42-
MAPK (E10; 1:2000; #9106) antibodies (Cell Signaling Technology).
Alcian Blue cartilage staining
4-dpf embryos were fixed in freshly prepared 4% PFA (in PBS) at
room temperature for 7 hours. The embryos were subsequently
thoroughly washed in 0.1% PBS-Tw and stained in freshly prepared
syringe-filtered 0.1% Alcian Blue solution (in acetic acid) at room
temperature for approximately 7 hours. Following complete
staining, the samples were rinsed in 100% ethanol, serially
rehydrated in PBS-Tw and stored at 4°C. The tissue was cleared in
0.05% trypsin (Invitrogen) for a minimum of 2 hours at 30°C until
the brain tissue was translucent, followed by short room-
temperature bleaching in 1% KOH in 3% hydrogen peroxide
solution to remove melanocyte pigmentation. The samples were
then thoroughly washed in PBS-Tw and mounted in 70% glycerol
to be stored and imaged.
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TRANSLATIONAL IMPACT
Clinical issue
The RASopathies, including cardio-facio-cutaneous syndrome (CFC), Noonan
syndrome and others, are a series of rare genetic syndromes caused by
germline mutations in the RAS-MAPK signalling pathway. Treatment of these
syndromes might benefit from the products in the intensive drug
development pipeline targeted at inhibiting the activated RAS-MAPK
signalling that underlies some cancers. The clinical features of the RASopathies
continue to progress after birth and, thus, there might be potential for both
pre- and post-natal treatment with such drugs. However, how these drugs
could be used in the context of the RASopathies, which are developmental
diseases, rather than in the context of anti-cancer therapy is unknown. 
Results
In this paper, the authors use zebrafish embryos as a tool to explore different
timing and treatment doses of a clinically active inhibitor of the RAS-MAPK
pathway – the MEK inhibitor PD0325901 – during development. Previously,
this group showed in zebrafish that mutated forms of BRAF and MEK found in
humans with CFC are sensitive to MEK inhibitors, but that a short treatment
time is necessary to prevent additional unwanted effects of MEK inhibition.
Here, they explore the potential for continuous MEK inhibitor treatment to
alleviate the defects caused by CFC-associated BRAF mutations. They find that
continuous and partial MEK inhibition can be tolerated during zebrafish
development, and can prevent the action of CFC-associated BRAF mutations at
multiple developmental stages. Thus, MEK inhibitors might have potential in
the management of CFC syndrome in very low doses that only partially inhibit
MEK activity. 
Implications and future directions
Animal models of disease are important preclinical tools for exploring how
drugs can be used for indications other than the diseases they were initially
designed to treat. This study suggests that very low doses of MEK inhibitors
can prevent the developmental effects of CFC-associated BRAF mutations
while not affecting the development of normal tissues that require MEK
signalling. Future directions include testing similar approaches in pre- and
post-natal preclinical mammalian models, and chemical optimisation of MEK
inhibitors to reduce toxic side effects.
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